Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23993249 | 1.00 | ESR1 (0.45) | ESR1PDGFRACDK5TYRO3KDM4C | |
| SCHEMBL30224397 | 0.83 | ESR1 (0.44) | ESR1PDGFRACDK5TYRO3KDM4C | |
| SCHEMBL31636216 | 0.83 | PDGFRA (0.48) | ESR1PDGFRACDK5TYRO3KDM4C | |
| SCHEMBL23993327 | 0.83 | ESR1 (0.44) | ESR1PDGFRACDK5TYRO3KDM4C | |
| SCHEMBL23994535 | 0.83 | ESR1 (0.44) | ESR1PDGFRACDK5TYRO3KDM4C | |
| SCHEMBL30224393 | 0.83 | ESR1 (0.44) | ESR1PDGFRACDK5TYRO3KDM4C | |
| SCHEMBL1965696 | 0.81 | ESR1 (0.43) | ESR1PDGFRACDK5TYRO3KDM4C | |
| SCHEMBL23993144 | 0.80 | ESR1 (0.41) | ESR1PDGFRACDK5TYRO3KDM4C | |
| SCHEMBL23993488 | 0.80 | ESR1 (0.41) | ESR1PDGFRACDK5TYRO3KDM4C | |
| SCHEMBL30224677 | 0.80 | ESR1 (0.41) | ESR1PDGFRACDK5TYRO3KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |